Post-anoxic myoclonus: A case presentation and review of management in the rehabilitation setting

Brain Injury

Volumn 20, Issue 2, 2006, Pages 213-217

  Polesin, Alena ^a   Stern, Michelle ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Rehabilitation Medicine ^*  (United States)

Author keywords

Anoxia; Case report; Myoclonus; Rehabilitation; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; DIAZEPAM; ETIRACETAM; PHENOBARBITAL; VALPROATE SEMISODIUM; ZONISAMIDE;

ADULT; BRAIN HYPOXIA; CARDIOPULMONARY ARREST; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INDEPENDENCE; MOBILIZATION; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; NOISE; QUALITY OF LIFE; REHABILITATION CENTER; RELAPSE; REVIEW; SEDATION; SELF CARE; SOMNOLENCE; STARTLE EPILEPSY;

EID: 31544454200     PISSN: 0883041X     EISSN: 1362301X     Source Type: Journal    
DOI: 10.1080/02699050500442972     Document Type: Review

References (18)

1. Lance, JW and Adams, RD. (1963) The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy Brain, 86, pp. 111-136.
2. Frucht, SJ.(2002) The clinical challenge of posthypoxic myoclonus. In Myoclonus and paroxysmal dyskinesias. Advances in Neurology. (pp. 85-88).
3. Werhahn, KJ and Brown, P and Thompson, PD and (1997) The clinical features and prognosis of chronic posthypoxic myoclonus Movement Disorders, 12, pp. 216-220.
4. Lance, JW and Adams, RD. (2001) Negative myoclonus in posthypoxic patients: Historical note Movement Disorders, 16, pp. 162-163.
5. Truong, DD and Kirby, M and Kanthasamy, A and Matsumoto, R. (2002) Posthypoxic myoclonus animal models Advances in Neurology, 89, pp. 295-306.
6. Welsh, JP and Yuen, G and Placantonakis, DG and Vu, TQ and Haiss, F and O'Hearn, E and (2002) Why do Purkinje cells die so easily after global brain ischemia? Aldolase C, EAAT4, and the cerebellar contribution to posthypoxic myoclonus. Advances in Neurology, 89, pp. 331-359.
7. Welsh, JP and Placantonakis, DG and Warsetsky, SI and Marquez, RG and Bernstein, L and Aicher, SA. (2002) The serotonin hypothesis of myoclonus Advances in Neurology, 89, pp. 307-329.
8. Pappert, EJ and Goetz, CG and Vu, TQ and Ling, ZD and Leurgans, S and Raman, R and (1999) Animal model of posthypoxic myoclonus: Effects of serotonergic antagonists Neurology, 52, pp. 16-21.
9. Melvin, H and Van Woert, MH and Rosenbaum, D and Chung, E. (1986) Biochemistry and therapeutics of posthypoxic myoclonus Advances in Neurology, 43, pp. 171-180.
10. Beretta, E and Regli, F and de Crousaz, G and Steck, AJ. (1981) Postanoxic myoclonus. Treatment of a case with 5-hydroxytriptophan and a decarboxylase inhibitor Journal of Neurology, 225, pp. 57-62.
11. Coletti, A and Mandelli, A and Minoli, G and Tredici, G. (1980) Post-anoxic action myoclonus (Lance-Adams syndrome) treated with levodopa and GABAergic drugs Journal of Neurology, 223, pp. 67-70.
12. Kanthasamy, AG and Vu, TQ and Yun, RJ and Truong, DD. (1995) Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus European Journal of Pharmacology, 297, pp. 219-224.
13. Rollinson, RD and Gilligan, BS. (1979) Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate Archives of Neurology, 36, pp. 44-45.
14. Bruni, J and Willmore, JL and Wilder, BJ. (1979) Treatment of postanoxic intention myoclonus with valproic acid Canadian Journal of Neurological Science, 6, pp. 39-42.
15. Jenner, P and Pratt, JA and Marsden, CD. (1986) Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT Advances in Neurology, 46, pp. 629-643.
16. Krauss, G.I. and Bergin, A and Kramer, R.E. and 2001 Suppression of posthypoxic and post-encephalitic myoclonus with levetiracetam Neurology, 56, pp. 411-412.
17. Frucht, SJ and Louis, ED and Chuang, C and (2001) A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus Neurology, 57, pp. 1112-1114.
18. Mimaki, T. (1998) Clinical pharmacology and therapeutic drug monitoring of zonisamide Therapeutic Drug Monitoring, 20, pp. 593-597.